Caution urged for for experimental cancer treatments

Compassionate access to unapproved cancer treatments could do more harm than good if appropriate safeguards are not in place, say Australian researchers.

The researchers, who include Dr Evan Doran from the University of Newcastle and PhD candidate Jan Lewis from the University of Sydney, write that patient access programs (PAP) challenge conventional clinical research and regulatory processes.

“If enough patients receive supply of a medication outside of a clinical trial setting, then opportunities are lost to